GEHC begins global clinical evaluation of StarGuide GX SPECT/CT

GE HealthCare (GEHC) is starting a clinical evaluation program for its StarGuide GX digital SPECT/CT system at five institutions on three continents. 

Participating sites will assess image quality, quantitative performance, dynamic imaging, and workflow at the following:

• Hadassah Medical Center, Israel
• Mayo Clinic, U.S.
• Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse, France
• Peking University First Hospital, China
• Rambam Health Care Campus, Israel

StarGuide GX uses dual-sided cadmium zinc telluride detectors and a dual-collimator design intended to eliminate manual collimator exchanges, according to the company. In research settings, it may also be evaluated for imaging alpha-emitting radionuclides such as actinium-225, GEHC said.

The system received the CE Mark in November 2025 and is pending U.S. Food and Drug Administration (FDA) 510(k) clearance.